Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center

Rebecca Jeun; Priyanka C. Iyer; Conor Best; Victor Lavis; Jeena M. Varghese; Sireesha Yedururi; Veronica Brady; Isabella C. Glitza Oliva; Ramona Dadu; Denai R. Milton; Kristy Brock; Sonali Thosani

doi:10.2217/imt-2021-0316

Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center

Rebecca Jeun, Priyanka C. Iyer, Conor Best, Victor Lavis, Jeena M. Varghese, Sireesha Yedururi, Veronica Brady, Isabella C. Glitza Oliva, Ramona Dadu, Denai R. Milton, Kristy Brock, Sonali Thosani

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on melanoma patients. Research design & methods: We conducted a retrospective review of 76 patients diagnosed with ICI-DM from April 2014 to December 2020. Results: 68% of patients presented in diabetic ketoacidosis, 16% had readmissions for hyperglycemia, and hypoglycemia occurred in 70% of patients after diagnosis. Development of ICI-DM did not impact overall survival or progression-free survival in melanoma patients. Conclusion: Development of ICI-DM is associated with long-term insulin dependence and pancreatic atrophy; the use of diabetes technology in this patient population can help improve glycemic control.

Original language	English (US)
Pages (from-to)	417-428
Number of pages	12
Journal	Immunotherapy
Volume	15
Issue number	6
DOIs	https://doi.org/10.2217/imt-2021-0316
State	Published - Apr 1 2023

Keywords

diabetic ketoacidosis
hypoglycemia
immune checkpoint inhibitor
insulin-dependent diabetes
pancreatic atrophy

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.2217/imt-2021-0316

Cite this

@article{a9b8893e77a34c7c8d4b35b23e40627d,

title = "Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center",

abstract = "Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on melanoma patients. Research design & methods: We conducted a retrospective review of 76 patients diagnosed with ICI-DM from April 2014 to December 2020. Results: 68% of patients presented in diabetic ketoacidosis, 16% had readmissions for hyperglycemia, and hypoglycemia occurred in 70% of patients after diagnosis. Development of ICI-DM did not impact overall survival or progression-free survival in melanoma patients. Conclusion: Development of ICI-DM is associated with long-term insulin dependence and pancreatic atrophy; the use of diabetes technology in this patient population can help improve glycemic control.",

keywords = "diabetic ketoacidosis, hypoglycemia, immune checkpoint inhibitor, insulin-dependent diabetes, pancreatic atrophy",

author = "Rebecca Jeun and Iyer, {Priyanka C.} and Conor Best and Victor Lavis and Varghese, {Jeena M.} and Sireesha Yedururi and Veronica Brady and {Glitza Oliva}, {Isabella C.} and Ramona Dadu and Milton, {Denai R.} and Kristy Brock and Sonali Thosani",

note = "Funding Information: This work was supported in part by the NIH/NCI under award no. P30CA016672. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2023 Future Medicine Ltd.",

year = "2023",

month = apr,

day = "1",

doi = "10.2217/imt-2021-0316",

language = "English (US)",

volume = "15",

pages = "417--428",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center

AU - Jeun, Rebecca

AU - Iyer, Priyanka C.

AU - Best, Conor

AU - Lavis, Victor

AU - Varghese, Jeena M.

AU - Yedururi, Sireesha

AU - Brady, Veronica

AU - Glitza Oliva, Isabella C.

AU - Dadu, Ramona

AU - Milton, Denai R.

AU - Brock, Kristy

AU - Thosani, Sonali

N1 - Funding Information: This work was supported in part by the NIH/NCI under award no. P30CA016672. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2023 Future Medicine Ltd.

PY - 2023/4/1

Y1 - 2023/4/1

N2 - Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on melanoma patients. Research design & methods: We conducted a retrospective review of 76 patients diagnosed with ICI-DM from April 2014 to December 2020. Results: 68% of patients presented in diabetic ketoacidosis, 16% had readmissions for hyperglycemia, and hypoglycemia occurred in 70% of patients after diagnosis. Development of ICI-DM did not impact overall survival or progression-free survival in melanoma patients. Conclusion: Development of ICI-DM is associated with long-term insulin dependence and pancreatic atrophy; the use of diabetes technology in this patient population can help improve glycemic control.

AB - Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on melanoma patients. Research design & methods: We conducted a retrospective review of 76 patients diagnosed with ICI-DM from April 2014 to December 2020. Results: 68% of patients presented in diabetic ketoacidosis, 16% had readmissions for hyperglycemia, and hypoglycemia occurred in 70% of patients after diagnosis. Development of ICI-DM did not impact overall survival or progression-free survival in melanoma patients. Conclusion: Development of ICI-DM is associated with long-term insulin dependence and pancreatic atrophy; the use of diabetes technology in this patient population can help improve glycemic control.

KW - diabetic ketoacidosis

KW - hypoglycemia

KW - immune checkpoint inhibitor

KW - insulin-dependent diabetes

KW - pancreatic atrophy

UR - http://www.scopus.com/inward/record.url?scp=85151805617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151805617&partnerID=8YFLogxK

U2 - 10.2217/imt-2021-0316

DO - 10.2217/imt-2021-0316

M3 - Article

C2 - 37013834

AN - SCOPUS:85151805617

SN - 1750-743X

VL - 15

SP - 417

EP - 428

JO - Immunotherapy

JF - Immunotherapy

IS - 6

ER -

Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this